EGFR Targeting TKI-Related Skin Toxicities in a Patient with Darker Skin: A Case Report

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2022 Apr 21

PMID 35448179

Authors

Arman Zereshkian

Alia Thawer

David M Hwang

Susanna Cheng

Affiliations

Soon will be listed here.

Abstract

Epidermal growth factor receptor (EGFR) targeting tyrosine kinase inhibitors (TKIs) can result in significant skin toxicities that may impact patients' quality of life. While these skin reactions are well documented in patients with lighter skin, there is a paucity of literature and images to guide clinicians in their assessment in patients with darker skin tones. Given that dermatological reactions in patients with darker skin are not well represented, this can result in the undertreatment or mistreatment of these otherwise common toxicities. Herein, we present a case of a female patient with a darker skin tone with metastatic non-small cell lung carcinoma (NSCLC) with EGFR-TKI-related skin toxicity and her clinical course.

References

Annunziata M, De Stefano A, Fabbrocini G, Leo S, Marchetti P, Romano M . Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer. Clin Drug Investig. 2019; 39(9):825-834. DOI: 10.1007/s40261-019-00811-7. View

Geisler A, Noor S . Cutaneous Manifestations of EGFR-Inhibitors in African Americans and Treatment Considerations. J Drugs Dermatol. 2020; 19(9):894-896. DOI: 10.36849/JDD.2020.10.36849/JDD.2020.5275. View

Jiang S, Walton R, Hueniken K, Baek J, McCartney A, Labbe C . Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer. Cancer Med. 2019; 8(18):7542-7555. PMC: 6912023. DOI: 10.1002/cam4.2603. View

Tseng L, Chen K, Wang C, Weng L . Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study. Medicine (Baltimore). 2020; 99(23):e20510. PMC: 7306373. DOI: 10.1097/MD.0000000000020510. View

Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C . Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Biosci Trends. 2018; 12(6):537-552. DOI: 10.5582/bst.2018.01246. View

Califano R, Tariq N, Compton S, Fitzgerald D, Harwood C, Lal R . Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs. 2015; 75(12):1335-48. PMC: 4532717. DOI: 10.1007/s40265-015-0434-6. View

Lertpichitkul P, Wititsuwannakul J, Asawanonda P, Rerknimitr P . Osimertinib-associated ashy dermatosis-like hyperpigmentation. JAAD Case Rep. 2020; 6(2):86-88. PMC: 7005333. DOI: 10.1016/j.jdcr.2019.11.008. View

Hayashi H, Nadal E, Gray J, Ardizzoni A, Caria N, Puri T . Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Clin Lung Cancer. 2021; 23(1):e69-e82. DOI: 10.1016/j.cllc.2021.10.009. View

Louie P, Wilkes R . Representations of race and skin tone in medical textbook imagery. Soc Sci Med. 2018; 202:38-42. DOI: 10.1016/j.socscimed.2018.02.023. View

10.

Chansky P, Mittal L, Werth V . Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis. Br J Dermatol. 2017; 176(4):853-854. PMC: 5843478. DOI: 10.1111/bjd.15433. View

11.

Melosky B, Banerji S, Blais N, Chu Q, Juergens R, Leighl N . Canadian consensus: a new systemic treatment algorithm for advanced mutated non-small-cell lung cancer. Curr Oncol. 2020; 27(2):e146-e155. PMC: 7253730. DOI: 10.3747/co.27.6007. View

12.

Waris W, Naik S, Idrees I, Taha H, Camosino L, Mehrishi A . Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer. Cutan Ocul Toxicol. 2009; 28(1):41-4. DOI: 10.1080/15569520802646552. View